MRI Drugs May Cause Death, Warns FDA

Magnetic Resonance Imaging (MRI) involves three substances that could be the cause for a fatal, albeit rare condition, warned US Food and Drug Administration (FDA).

The FDA said new warnings for gadolinium-based contrast agents (GBCAs) needed to highlight the risk of nephrogenic systemic fibrosis (NSF) if the drug is given to certain patients with kidney disease.

About Magnetic Resonance Imaging(MRI)
Encyclopedia section of medindia gives general info about Magnetic Resonance Imaging

The labels, said the agency, "will emphasize the need to screen patients to detect these types of kidney dysfunction before administration."

The three intravenous drugs involved in the FDA action are Magnevist, Omniscan, and Optimark, which are used ahead of MRIs to help detect abnormalities of body organs, blood vessels and other tissues.

Source-AFP

Nephrogenic Systemic Fibrosis Increases Death Rates in Kidney Patients
Nephrogenic systemic fibrosis (NSF) is a newly identified debilitating and painful condition that affects patients with kidney failure and is characterized by a thickening and hardening of the skin.

Clinical Trials | Drug Trials - Types Protocol Development and Approval FAQs
Clinical trials are experiments that yield useful information to clinicians if a particular treatment is of any value to a patient.

New Magnetic Resonance Imaging Developed
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory and the University of California at Berkeley have developed a potential new magnetic resonance imaging